Core Clinical Breakthroughs
1. Dual-Targeting CD19 / BCMA Tandem CAR-T Vectors
Addresses antigen escape and tumor mutation. By simultaneously targeting dual cell surface markers, sustained complete remission (CR) rates are significantly elevated, overcoming single-target relapse common in conventional therapies.
2. Advanced Cytokine Release Syndrome (CRS) Prevention & PICU Safety Net
Supported by state-of-the-art hematology intensive care units (PICU) with real-time IL-6 monitoring and preemptive tocilizumab protocols, keeping severe Grade 3/4 neurotoxicity and CRS below 4.2%.
3. Source Innovation & Rapid 14-Day Cell Manufacturing
Leveraging direct synergy with Shanghai Zhangjiang National Biopharma Valley, autologous T-cell apheresis to final clinical release is compressed to 12-14 calendar days, reducing waiting periods for urgent patients.
Academic Leadership & Faculty Oversight
Prof. Liang Aibin, M.D., Ph.D.
Lead investigator of multiple landmark national CAR-T trials. Author of over 80 SCI publications including Lancet Oncology and Blood. Personally reviews each international candidate dossier.
Apply for Confidential CAR-T Clinical Case Evaluation
Submit existing bone marrow biopsy, flow cytometry, or PET-CT reports. Our clinical case managers will coordinate senior faculty review within 48 hours.